TGFB1 and Alzheimer disease: Despite conflicting findings regarding TGF-β1 levels at various stages of AD, this anti-inflammatory cytokine has emerged as one of the leading 20 CSF candidate biomarkers associated with the rate of cognitive decline in dementia patients, as demonstrated in longitudinal studies [131].